Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Core One Labs (CSE:COOL) subsidiary Vocan Biotechnologies has converted psilocin developed by Awakened Biosciences into viable API psilocybin
  • 125g of psilocin can be transformed into about 160g of psilocybin
  • The quantity and purity of psilocybin being produced in Vocan’s lab emphasize the efficiency of their production technology
  • Core One anticipates that furnishing Vocan’s current lab facilities will result in significantly increased yields
  • Core One Labs delivers psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy
  • Core One (COOL) opened trading at C$0.40 per share

Core One Labs (CSE:COOL) subsidiary Vocan Biotechnologies has converted psilocin developed by Awakened Biosciences into viable API psilocybin.

Awakened has produced approximately 220 grams of a psilocin precursor, which it can convert into a minimum of 125g of psilocin, the psychoactive ingredient in psilocybin. Using Vocan’s production technology, this can be transformed into about 160 g of contaminant-free psilocybin.

To date, Vocan has successfully transformed psilocin into psilocybin at their lab.

The successful test batch results and the quantity and purity of psilocybin being produced in Vocan’s lab emphasize the efficiency of their production technology. Core One anticipates furnishing Vocan’s current lab facilities with small-scale production equipment will result in significantly increased yields and anticipates mass production capabilities with the engagement of GMP-compliant contract development and manufacturing organization (CDMO).

Joel Shacker, Core One CEO, commented on the news.

“The renaissance of psychedelics medicine as an alternative means to addressing mental health afflictions has been making significant strides in the last decade, and I am very confident when I say that Core One is doing its part from an early onset.”

He added,

“Our team of scientists, and their groundbreaking collaborations are putting Core One ‘on the map’; not only as leading innovators in psychedelics research and development, but also as a ‘one stop shop’ for patients, physicians and researchers, alike. With a growing body of research, and an increased openness to evaluate psychedelic treatments on its merits, rather than on historic myths and misnomers, Core One feels that demand for access to psychedelic medicines and psychedelic-assisted treatments will also continue increase. We are committed to meeting the anticipated demands and by doing so we will continue to grow shareholder value.”

Core One Labs is focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy.

Core One (COOL) opened trading at C$0.40 per share.


More From The Market Herald
Featured Video Play Icon

" OpSens (TSX:OPS) announces first SavvyWire procedure in the U.S.

OpSens (OPS) is announcing the first SavvyWire procedure in the U.S.

" Israeli Technology company BYND Cannasoft (CSE:BYND) acquires Zigi Carmel Investments Ltd.

BYND Cannasoft (BYND) closes the acquisition of Zigi Carmel Investments with a value of US $28 million.

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.
Featured Video Play Icon

" Rapid Dose Therapeutics (CSE:DOSE) to supply leading gas and convenience store retailer

Rapid Dose (DOSE) has signed a supplier agreement with a leading gas and convenience store retailer.